Targeting NCCA-ATP channel for organ protection following ischemic episode
US12121526B2 · kind B2 · utility
0Cited by
40References
20Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Dec 21, 2020 |
| Grant date | Oct 22, 2024 |
| Priority date | — |
| Expiry date | Nov 28, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1. Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.